Ranbaxy Laboratories Ltd.’s announcement that it has entered into a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation appears to put the Daiichi Sankyo Co. Ltd. subsidiary on pace to pay the second highest settlement for pharmaceutical good manufacturing practice violations.
Ranbaxy would join Schering-Plough Corp.in the second spot on the list of most expensive settlements of drug manufacturing violations,...